tetano
Editor, Senior Moderator
Trop Med Health
. 2022 Mar 21;50(1):24.
doi: 10.1186/s41182-022-00415-6.
Parental COVID-19 vaccine hesitancy for children with neurodevelopmental disorders: a cross-sectional survey
Mohammad Ali[SUP] 1 2 [/SUP], Tasnuva Shamarukh Proma[SUP] 3 [/SUP], Zarin Tasnim[SUP] 4 [/SUP], Md Ariful Islam[SUP] 5 [/SUP], Tania Akter Urmi[SUP] 6 [/SUP], Sohel Ahmed[SUP] 7 [/SUP], Abu-Sufian Sarkar[SUP] 8 [/SUP], Atia Sharmin Bonna[SUP] 9 [/SUP], Umme Salma Khan[SUP] 10 [/SUP]
Affiliations
Abstract
Background: Little is known about parental coronavirus disease 2019 (COVID-19) vaccine hesitancy in children with neurodevelopmental disorders (NDD). This survey estimated the prevalence and predictive factors of vaccine hesitancy among parents of children with NDD.
Methods: A nationally representative cross-sectional survey was conducted from October 10 to 31, 2021. A structured vaccine hesitancy questionnaire was used to collect data from parents aged ≥ 18 years with children with NDD. In addition, individual face-to-face interviews were conducted at randomly selected places throughout Bangladesh. Multiple logistic regression analysis was conducted to identify the predictors of vaccine hesitancy.
Results: A total of 396 parents participated in the study. Of these, 169 (42.7%) parents were hesitant to vaccinate their children. Higher odds of vaccine hesitancy were found among parents who lived in the northern zone (AOR = 17.15, 95% CI = 5.86-50.09; p < 0.001), those who thought vaccines would not be safe and effective for Bangladeshi children (AOR = 3.22, 95% CI = 1.68-15.19; p < 0.001), those who were either not vaccinated or did not receive the COVID-19 vaccine themselves (AOR = 12.14, 95% CI = 8.48-17.36; p < 0.001), those who said that they or their family members had not tested positive for COVID-19 (AOR = 2.13, 95% CI = 1.07-4.25), and those who did not lose a family member to COVID-19 (AOR = 2.12, 95% CI = 1.03-4.61; p = 0.040). Furthermore, parents who were not likely to believe that their children or a family member could be infected with COVID-19 the following year (AOR = 4.99, 95% CI = 1.81-13.77; p < 0.001) and who were not concerned at all about their children or a family member being infected the following year (AOR = 2.34, 95% CI = 1.65-8.37; p = 0.043) had significantly higher odds of COVID-19 vaccine hesitancy.
Conclusions: Given the high prevalence of vaccine hesitancy, policymakers, public health practitioners, and pediatricians can implement and support strategies to ensure that children with NDD and their caregivers and family members receive the COVID-19 vaccine to fight pandemic induced hazards.
Keywords: Bangladesh; COVID-19; Neurodevelopmental disorders; Parental vaccine hesitancy; Pediatrics.
. 2022 Mar 21;50(1):24.
doi: 10.1186/s41182-022-00415-6.
Parental COVID-19 vaccine hesitancy for children with neurodevelopmental disorders: a cross-sectional survey
Mohammad Ali[SUP] 1 2 [/SUP], Tasnuva Shamarukh Proma[SUP] 3 [/SUP], Zarin Tasnim[SUP] 4 [/SUP], Md Ariful Islam[SUP] 5 [/SUP], Tania Akter Urmi[SUP] 6 [/SUP], Sohel Ahmed[SUP] 7 [/SUP], Abu-Sufian Sarkar[SUP] 8 [/SUP], Atia Sharmin Bonna[SUP] 9 [/SUP], Umme Salma Khan[SUP] 10 [/SUP]
Affiliations
- PMID: 35313989
- DOI: 10.1186/s41182-022-00415-6
Abstract
Background: Little is known about parental coronavirus disease 2019 (COVID-19) vaccine hesitancy in children with neurodevelopmental disorders (NDD). This survey estimated the prevalence and predictive factors of vaccine hesitancy among parents of children with NDD.
Methods: A nationally representative cross-sectional survey was conducted from October 10 to 31, 2021. A structured vaccine hesitancy questionnaire was used to collect data from parents aged ≥ 18 years with children with NDD. In addition, individual face-to-face interviews were conducted at randomly selected places throughout Bangladesh. Multiple logistic regression analysis was conducted to identify the predictors of vaccine hesitancy.
Results: A total of 396 parents participated in the study. Of these, 169 (42.7%) parents were hesitant to vaccinate their children. Higher odds of vaccine hesitancy were found among parents who lived in the northern zone (AOR = 17.15, 95% CI = 5.86-50.09; p < 0.001), those who thought vaccines would not be safe and effective for Bangladeshi children (AOR = 3.22, 95% CI = 1.68-15.19; p < 0.001), those who were either not vaccinated or did not receive the COVID-19 vaccine themselves (AOR = 12.14, 95% CI = 8.48-17.36; p < 0.001), those who said that they or their family members had not tested positive for COVID-19 (AOR = 2.13, 95% CI = 1.07-4.25), and those who did not lose a family member to COVID-19 (AOR = 2.12, 95% CI = 1.03-4.61; p = 0.040). Furthermore, parents who were not likely to believe that their children or a family member could be infected with COVID-19 the following year (AOR = 4.99, 95% CI = 1.81-13.77; p < 0.001) and who were not concerned at all about their children or a family member being infected the following year (AOR = 2.34, 95% CI = 1.65-8.37; p = 0.043) had significantly higher odds of COVID-19 vaccine hesitancy.
Conclusions: Given the high prevalence of vaccine hesitancy, policymakers, public health practitioners, and pediatricians can implement and support strategies to ensure that children with NDD and their caregivers and family members receive the COVID-19 vaccine to fight pandemic induced hazards.
Keywords: Bangladesh; COVID-19; Neurodevelopmental disorders; Parental vaccine hesitancy; Pediatrics.